Aidport Sp. z o.o.
- Address
- Ul Ksiedza Stanisława Kozierowskiego 24, 60-185 Poznan, Poland
Hemic and Lymphatic Diseases
At Aidport Sp. z o.o. in Poznan, the clinical research focus is centered on Hemic and Lymphatic Diseases, with studies exploring treatment options for myelofibrosis and related blood disorders. The trials are designed to assess whether new therapies can improve disease control and support patients with difficult-to-manage blood conditions.
- Research in myelofibrosis with moderate thrombocytopenia
- Studies involving JAK inhibitor-naïve patients
- Evaluation of a new treatment approach for effectiveness and safety
This work reflects a focused effort to improve care for people with hematologic malignancies, while helping clarify how emerging therapies may benefit patients who have not previously received JAK inhibitor treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 8 therapeutic areas and 15 of 119 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 115 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 33 by active trials.
- 1Novartis Pharma AG3active
lock +32 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG5trials
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aidport Sp. z o.o.
lock Showing 1 of 77 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 119 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 18 | Unknown | 2020-11-16 | 2025-12-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.